1. Home
  2. FBIO
  3. FBIO News

Latest Fortress Biotech Inc. (FBIO) News on November 27, 2025

Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates
FBIO

Zacks

13 days ago

Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates

FBIO

Associated Press Finance

13 days ago

Fortress Biotech: Q3 Earnings Snapshot

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

13 days ago

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

15 days ago

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Kamada (KMDA) Misses Q3 Earnings Estimates
FBIO

Zacks

17 days ago

Kamada (KMDA) Misses Q3 Earnings Estimates

Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
FBIO

Zacks

21 days ago

Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
FBIO

GlobeNewswire

21 days ago

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
FBIO

GlobeNewswire

22 days ago

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates
FBIO

Zacks

23 days ago

Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates
FBIO

Zacks

a month ago

Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
FBIO

GlobeNewswire

a month ago

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
FBIO

GlobeNewswire

a month ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout

Journey Medical Corporation to Participate in October 2025 Investor Conferences
FBIO

GlobeNewswire

2 months ago

Journey Medical Corporation to Participate in October 2025 Investor Conferences

FBIO

MT Newswires

2 months ago

Top Midday Decliners

Journey Medical to Join Russell 2000® and Russell 3000® Indexes
FBIO

GlobeNewswire

5 months ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
FBIO

GlobeNewswire

5 months ago

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock
FBIO

Zacks

5 months ago

Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
FBIO

GlobeNewswire

6 months ago

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum
FBIO

Zacks

6 months ago

Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum

FBIO

MT Newswires

6 months ago

Fortress Biotech Closes Sale of Checkpoint Therapeutics Unit

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
FBIO

GlobeNewswire

6 months ago

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

Fortress Biotech First Quarter 2025 Earnings: Beats Expectations
FBIO

Simply Wall St.

6 months ago

Fortress Biotech First Quarter 2025 Earnings: Beats Expectations

New Strong Sell Stocks for May 16th
FBIO

Zacks

6 months ago

New Strong Sell Stocks for May 16th

Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates
FBIO

Zacks

6 months ago

Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates

FBIO

Associated Press Finance

6 months ago

Fortress Biotech: Q1 Earnings Snapshot

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

6 months ago

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

6 months ago

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
FBIO

GlobeNewswire

6 months ago

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
FBIO

GlobeNewswire

7 months ago

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
FBIO

GlobeNewswire

7 months ago

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

This Fortress Biotech Insider Increased Their Holding By 26% Last Year
FBIO

Simply Wall St.

8 months ago

This Fortress Biotech Insider Increased Their Holding By 26% Last Year

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
FBIO

GlobeNewswire

8 months ago

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates
FBIO

Zacks

8 months ago

Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

8 months ago

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
FBIO

GlobeNewswire

8 months ago

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

8 months ago

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

Fortress Biotech Inc (FBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings
FBIO

GuruFocus.com

8 months ago

Fortress Biotech Inc (FBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
FBIO

GlobeNewswire

8 months ago

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
FBIO

GlobeNewswire

8 months ago

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

FBIO

MT Newswires

8 months ago

Sector Update: Health Care Stocks Gain Monday Afternoon

FBIO

MT Newswires

8 months ago

Fortress Biotech, Partex Team Up for Asset Identification, Evaluation Using AI

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
FBIO

GlobeNewswire

8 months ago

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

Biotech Alert: Searches spiking for these stocks today
FBIO

TipRanks

8 months ago

Biotech Alert: Searches spiking for these stocks today

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
FBIO

GlobeNewswire

9 months ago

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

FBIO

MT Newswires

9 months ago

Update: Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday

Sun Pharma to Acquire Checkpoint Therapeutics
FBIO

PR Newswire

9 months ago

Sun Pharma to Acquire Checkpoint Therapeutics

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
FBIO

GlobeNewswire

9 months ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
FBIO

GlobeNewswire

9 months ago

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
FBIO

GlobeNewswire

9 months ago

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
FBIO

GlobeNewswire

9 months ago

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
FBIO

GlobeNewswire

10 months ago

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mustang Bio Announces Closing of $8 Million Public Offering
FBIO

GlobeNewswire

10 months ago

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio Announces Pricing of $8 Million Public Offering
FBIO

GlobeNewswire

10 months ago

Mustang Bio Announces Pricing of $8 Million Public Offering

Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex
FBIO

TipRanks

10 months ago

Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex

Fortress doses first subject in Phase II CMV vaccine trial
FBIO

Clinical Trials Arena

10 months ago

Fortress doses first subject in Phase II CMV vaccine trial

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
FBIO

GlobeNewswire

10 months ago

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
FBIO

GlobeNewswire

10 months ago

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Mustang Bio Announces Reverse Stock Split
FBIO

GlobeNewswire

10 months ago

Mustang Bio Announces Reverse Stock Split

FDA accepts Sentynl’s Menkes disease therapy NDA for priority review
FBIO

Pharmaceutical Technology

a year ago

FDA accepts Sentynl’s Menkes disease therapy NDA for priority review

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
FBIO

GlobeNewswire

a year ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease
FBIO

PR Newswire

a year ago

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
FBIO

GlobeNewswire

a year ago

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations
FBIO

Simply Wall St.

a year ago

Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations

FBIO

Associated Press Finance

a year ago

Fortress Biotech: Q3 Earnings Snapshot

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

a year ago

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

a year ago

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
FBIO

GlobeNewswire

a year ago

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

a year ago

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Mustang Bio Receives Positive Listing Determination from Nasdaq
FBIO

GlobeNewswire

a year ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
FBIO

GlobeNewswire

a year ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
FBIO

GlobeNewswire

a year ago

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m
FBIO

Simply Wall St.

a year ago

Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m

Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares
FBIO

GuruFocus.com

a year ago

Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
FBIO

GlobeNewswire

a year ago

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
FBIO

GlobeNewswire

a year ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
FBIO

GlobeNewswire

a year ago

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
FBIO

GlobeNewswire

a year ago

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

FBIO

MT Newswires

a year ago

Fortress Biotech Files Registration Statement on Behalf of Selling Shareholders

Fortress Biotech to Participate in October 2024 Investor Conferences
FBIO

GlobeNewswire

a year ago

Fortress Biotech to Participate in October 2024 Investor Conferences

FBIO

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 09/26/2024

FBIO

MT Newswires

a year ago

Fortress Biotech Prices Registered Direct Offering, Private Placements; Shares Fall

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
FBIO

GlobeNewswire

a year ago

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
FBIO

GlobeNewswire

a year ago

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
FBIO

GlobeNewswire

a year ago

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FBIO

GlobeNewswire

a year ago

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FBIO

GlobeNewswire

a year ago

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
FBIO

GlobeNewswire

a year ago

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Avenue Therapeutics to Participate in Upcoming Investor Conferences
FBIO

GlobeNewswire

a year ago

Avenue Therapeutics to Participate in Upcoming Investor Conferences

Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock
FBIO

Zacks

a year ago

Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock

Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates
FBIO

Zacks

a year ago

Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates

FBIO

Associated Press Finance

a year ago

Fortress Biotech: Q2 Earnings Snapshot

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

a year ago

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

a year ago

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
FBIO

GlobeNewswire

a year ago

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

a year ago

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
FBIO

Zacks

a year ago

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024
FBIO

GlobeNewswire

a year ago

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
FBIO

GlobeNewswire

a year ago

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
FBIO

GlobeNewswire

a year ago

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

FBIO

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 07/16/2024

Share on Social Networks: